EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd
Rhea-AI Summary
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has signed a Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd, a Singapore-based biotech company. The LOI includes a 120-day exclusivity period during which Chemokine cannot engage in discussions with other potential buyers.
Chemokine, founded by Professor Kah Meng Lim, specializes in molecular supplements and gene modulating formulations. The company has previously granted EUDA exclusive worldwide distribution rights to its next-generation immune health supplement, which EUDA will market as Euda Helixé. The supplement combines molecular deer placenta, marine collagen, and bioactive antioxidants, utilizing a gene activation model designed to modulate gene expression.
Positive
- Potential acquisition of Chemokine would expand EUDA's biotech capabilities
- Existing exclusive worldwide distribution rights for Euda Helixé product
- 120-day exclusivity period secured for acquisition discussions
- Integration with established molecular medicine expertise through Prof. Lim
Negative
- No disclosed financial terms or valuation for the potential acquisition
- Acquisition is still in early stages with only LOI signed
- Due diligence process and final agreement yet to be completed
Insights
EUDA's LOI to acquire Chemokine represents early-stage M&A interest with potential synergies but remains highly preliminary.
EUDA Health's signed Letter of Intent (LOI) to potentially acquire Chemokine Pte Ltd marks an early exploratory step in what could become a strategic acquisition. The 120-day exclusivity period provides EUDA sufficient time to conduct thorough due diligence while preventing Chemokine from entertaining competing offers.
The companies already have an established relationship, with EUDA holding exclusive worldwide distribution rights to Chemokine's next-generation immune health supplement, which EUDA markets as Euda Helixé. This existing partnership potentially reduces integration risk and suggests potential synergies are already identified.
Chemokine's scientific foundation appears substantial, led by Prof. Kah Meng Lim, who holds a Ph.D. in Molecular Medicine from the National University of Singapore and has research experience with A*STAR, Singapore's respected national R&D agency. This scientific credibility could enhance EUDA's product portfolio and intellectual property assets.
The Euda Helixé product itself combines molecular deer placenta, marine collagen, and various bioactive compounds, utilizing a gene activation model aimed at modulating gene expression. While these claims are scientifically complex, they align with premium positioning in the growing nutraceutical market.
However, investors should note this is merely an LOI, representing the most preliminary stage of M&A activity. No financial terms were disclosed, and the completion of this acquisition remains contingent on due diligence outcomes and subsequent definitive agreements. The news indicates strategic intent but offers minimal concrete details about valuation or integration plans.
SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”).
EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition.
Chemokine is a Singapore based biotech company focused on molecular supplements and gene modulating formulations including, but not limited to, a next-generation immune health supplement it earlier granted EUDA exclusive worldwide distribution rights to, which EUDA and its subsidiaries will market under the brand name, Euda Helixé.
Chemokine was founded by its major shareholder, Professor Kah Meng Lim, a molecular medicine researcher with deep scientific roots. Prof. Lim earned his Ph.D. in Molecular Medicine from the National University of Singapore and spent years in research roles under Singapore’s national R&D agency, A*STAR. His work bridges academic science and consumer health innovation, and he is widely respected for translating complex biological discoveries into practical health applications.
What Makes Euda Helixé Different
Euda Helixé is designed to support energy, immune resilience, and cellular health using a formulation that goes beyond traditional supplements. It combines molecular deer placenta, marine collagen and bioactive antioxidants like astaxanthin, L-glutathione, grape seed oil, sea-buckthorn oil and refined avocado oil which it delivers through a capsule system that protects and delivers the ingredients for maximum absorption
Euda Helixé is built on a gene activation model designed to modulate gene expression by activating beneficial genes while silencing harmful ones.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Chemokine, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com
FAQ
What is the potential acquisition target for EUDA Health Holdings (NASDAQ: EUDA)?
How long is the exclusivity period in EUDA's LOI with Chemokine?
Who is the founder of Chemokine Pte Ltd?
What is Euda Helixé and what makes it unique?
What is the current relationship between EUDA and Chemokine?
